查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726168

糖尿病前期市場規模、佔有率、趨勢分析報告：按藥物類別、年齡層、地區和細分市場預測，2025 年至 2030 年

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adult, Elderly), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 134 Pages | 商品交期: 2-10個工作天內

價格

糖尿病前期市場的成長與趨勢

根據 Grand View Research, Inc. 的新報告，預計到 2030 年全球糖尿病前期市場規模將達到 5.857 億美元。

預計 2025 年至 2030 年間，市場複合年成長率將達到 10.9%。推動市場成長的因素有很多。主要促進因素之一是糖尿病前期盛行率的上升和肥胖率的增加。肥胖與糖尿病的發展有關。例如，根據聖路易斯華盛頓大學 2023 年 6 月的一項研究，美國有超過 3700 萬人患有糖尿病，其中超過 40% 的人肥胖，這種情況與多達一半的糖尿病病例有關。據估計，大約有 9,600 萬美國人（約佔成年人的三分之一）患有糖尿病前期。肥胖通常與久坐的生活方式和不良的飲食習慣有關，是導致糖尿病前期的重要危險因子。糖尿病前期患者的增多與全球肥胖症的流行同時發生，顯示了這兩個健康問題之間的關聯。

此外，遺傳傾向和家族病史也扮演重要角色。雖然生活方式起著很大的作用，但遺傳因素也會影響個人對糖尿病前期的易感性，使某些人群更容易患上糖尿病前期。

糖尿病前期市場報告重點

  • 根據藥物類別，雙胍類藥物將在 2024 年佔據市場主導地位，銷售額佔有率最大，為 78.8%。Metformin屬於雙胍類藥物，是糖尿病的第一線治療藥物。Metformin是用於治療和減緩糖尿病前期進展的最常用的仿單標示外用藥。
  • 從年齡層來看，成年人群體在 2024 年佔據市場主導地位，銷售額佔最大。成年人久坐不動和易患病的生活方式日益盛行是這一年齡層的主要成長要素。糖尿病前期盛行率的提高和人們認知的提高正在推動這一領域的成長。
  • 由於先進的醫療基礎設施、較高的認知度以及較高的臨床測試研究活動，北美在 2024 年佔據了市場主導地位，收入佔有率為 41.3%。該地區擁有先進且強大的研究基礎設施。社區計畫和支持團體鼓勵糖尿病前期患者做出永續的生活方式改變，例如健康飲食和定期進行體能活動。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 糖尿病前期市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

4. 糖尿病前期市場：藥物類別業務分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018 年至 2030 年藥品類別市場規模、預測與趨勢分析
  • 雙胍
  • 胰島素增敏劑
  • Glucagon-Like Peptide-1促效劑（GLP-1）
  • SGLT2抑制劑
  • DPP-4抑制劑
  • 其他

第5章糖尿病前期市場：依年齡層別進行的業務分析

  • 2024 年及 2030 年各年齡層市場佔有率
  • 年齡層細分儀表板
  • 市場規模、預測及趨勢分析（依年齡層，2018-2030 年）
  • 幼兒（12-18歲）
  • 成人（18-49歲）
  • 老年人（50歲或以上）

第6章 糖尿病前期市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novo Nordisk A/S
    • ValbIoTis
    • RESVERLOGIX
    • Caelus Health
    • Scimar
    • Boston Pharmaceuticals
    • APHAIA PHARMA AG
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
Product Code: GVR-4-68040-221-4

Prediabetes Market Growth & Trends:

The global prediabetes market size is anticipated to reach USD 585.7 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.9% from 2025 to 2030. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights:

  • Based on the drug class, the diguanide segment led the market with the largest revenue share of 78.8% in 2024. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes.
  • Based on the age group, the adult segment led the market with the largest revenue share in 2024. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment.
  • North America dominated the market with the revenue share of 41.3% in 2024, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Age Group
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prediabetes Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Prediabetes Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Diguanide
    • 4.4.1. Diguanide Market, 2018 - 2030 (USD Million)
  • 4.5. Thiazolidinediones
    • 4.5.1. Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • 4.6. Glucagon-like peptide-1 agonists (GLP-1)
    • 4.6.1. Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • 4.7. SGLT2 inhibitors
    • 4.7.1. SGLT2 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. DPP-4 inhibitors
    • 4.8.1. DPP-4 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prediabetes Market: Age Group Business Analysis

  • 5.1. Age Group Market Share, 2024 & 2030
  • 5.2. Age Group Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Age Group, 2018 to 2030 (USD Million)
  • 5.4. Children (12-18 years)
    • 5.4.1. Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • 5.5. Adults (18-49)
    • 5.5.1. Adults (18-49) Market, 2018 - 2030 (USD Million)
  • 5.6. Elderly (50+)
    • 5.6.1. Elderly (50+) Market, 2018 - 2030 (USD Million)

Chapter 6. Prediabetes Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novo Nordisk A/S
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Valbiotis
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. RESVERLOGIX
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Caelus Health
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Scimar
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Boston Pharmaceuticals
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. APHAIA PHARMA AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AstraZeneca
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Bristol-Myers Squibb Company
      • 7.5.9.1. Participant's overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Prediabetes Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 Global Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 6 North America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 8 North America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 9 U.S. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 U.S. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 11 Canada Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Canada Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 13 Mexico Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 Mexico Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 15 Europe Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Europe Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 18 U.K. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 U.K. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 20 Germany Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Germany Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 22 France Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 France Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 24 Italy Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 Italy Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 26 Spain Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Spain Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 28 Denmark Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Denmark Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 30 Norway Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Norway Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 32 Sweden Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Sweden Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 37 Japan Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Japan Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 39 China Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 China Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 41 India Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 43 South Korea Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 44 South Korea Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 45 Australia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Australia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 47 Thailand Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Thailand Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 49 Latin America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Latin America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 52 Brazil Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Brazil Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 54 Argentina Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Argentina Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 59 South Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 South Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 63 UAE Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 UAE Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prediabetes Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Drug Class and Age Group Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Prediabetes Market Dynamics
  • Fig. 12 Prediabetes Market: Porter's Five Forces Analysis
  • Fig. 13 Prediabetes Market: PESTLE Analysis
  • Fig. 14 Prediabetes Market: Drug Class Segment Dashboard
  • Fig. 15 Prediabetes Market: Drug Class Market Share Analysis, 2024 & 2030
  • Fig. 16 Diguanide Market, 2018 - 2030 (USD Million)
  • Fig. 17 Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • Fig. 18 Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • Fig. 19 SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 20 DPP-4 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 21 Others Market, 2018 - 2030 (USD Million)
  • Fig. 22 Prediabetes Market: Age Group Segment Dashboard
  • Fig. 23 Prediabetes Market: Age Group Market Share Analysis, 2024 & 2030
  • Fig. 24 Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • Fig. 25 Adults (18-49) Market, 2018 - 2030 (USD Million)
  • Fig. 26 Elderly (50+) Market, 2018 - 2030 (USD Million)
  • Fig. 27 Prediabetes Market Revenue, By Region
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Country Dynamics
  • Fig. 32 U.S. Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Country Dynamics
  • Fig. 34 Canada Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Country Dynamics
  • Fig. 36 Mexico Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Country Dynamics
  • Fig. 39 UK Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Country Dynamics
  • Fig. 41 Germany Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 42 France Country Dynamics
  • Fig. 43 France Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Country Dynamics
  • Fig. 45 Italy Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain Country Dynamics
  • Fig. 47 Spain Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Country Dynamics
  • Fig. 49 Denmark Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Country Dynamics
  • Fig. 51 Norway Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Country Dynamics
  • Fig. 53 Sweden Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Country Dynamics
  • Fig. 56 Japan Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 57 China Country Dynamics
  • Fig. 58 China Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 59 India Country Dynamics
  • Fig. 60 India Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea Country Dynamics
  • Fig. 62 South Korea Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia Country Dynamics
  • Fig. 64 Australia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand Country Dynamics
  • Fig. 66 Thailand Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil Country Dynamics
  • Fig. 69 Brazil Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Country Dynamics
  • Fig. 71 Argentina Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Country Dynamics
  • Fig. 74 South Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Country Dynamics
  • Fig. 76 Saudi Arabia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Country Dynamics
  • Fig. 78 UAE Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key Country Dynamics
  • Fig. 80 Kuwait Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 81 Company Categorization
  • Fig. 82 Company Market Position Analysis
  • Fig. 83 Strategic Framework